BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12007948)

  • 21. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.
    Syed AM; Puthawala A; Sharma A; Gamie S; Londrc A; Cherlow JM; Damore SJ; Nazmy N; Sheikh KM; Ko SJ
    Cancer Control; 2001; 8(6):511-21. PubMed ID: 11807421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.
    Myers MA; Hagan MP; Todor D; Gilbert L; Mukhopadhyay N; Randolf J; Heimiller J; Anscher MS
    Brachytherapy; 2012; 11(4):292-8. PubMed ID: 22464911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate.
    Serin M; Erkal HS; Sak SD; Cakmak A; Göğüş O; Akkaya A
    Urol Int; 1997; 58(1):30-3. PubMed ID: 9058517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
    Murgic J; Morton G; Loblaw A; D'Alimonte L; Ravi A; Wronski M; Davidson M; Haider M; Commisso K; Zhang L; Chung HT
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):561-567. PubMed ID: 30244878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erectile function after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
    Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
    Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ
    J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
    Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
    Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
    Mendez LC; Ravi A; Chung H; Tseng CL; Wronski M; Paudel M; McGuffin M; Cheung P; Loblaw A; Morton G
    Brachytherapy; 2018; 17(2):291-297. PubMed ID: 29137956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
    Morton GC; Hoskin PJ
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erectile function after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
    Jabbari S; Hsu IC; Kawakami J; Weinberg VK; Speight JL; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2009; 8(4):339-44. PubMed ID: 19428310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.